CJC-1295 without DAC + Ipamorelin

The blend contains two molecules with different mechanisms of action. CJC-1295 no DAC is an analogue of growth hormone-releasing hormone (GHRH). Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor.

Mechanism of action under investigation

Research is being carried out to investigate how these two pathways complement each other. A GHRH analogue and a secretagogue activate different signalling pathways, both of which result in the release of growth hormone by the pituitary gland. By combining them, researchers can demonstrate the interaction between the two pathways in a single experiment.

Ipamorelin is often described as a selective molecule in this context, as research has shown it to act in a relatively targeted manner on this pathway. This description relates to the mechanism of action as studied in scientific research and does not constitute evidence of efficacy in humans.

Because the blend combines two molecules, interpreting the results is more complex than with a single peptide: an observed effect may stem from one component, the other, or both. Researchers overcome this by comparing the blend with the individual components in separate experiments.

The combination of a GHRH analogue with a growth hormone secretagogue is a classic topic in endocrine research. Both components have been studied extensively in their own right; the blend combines them into a single standardised product.

• Research focus: complementary activation of the GHRH and ghrelin pathways.
• Research focus: the pulsatile regulation of growth hormone (preclinical).
• Research focus: the selectivity of secretagogues such as Ipamorelin.

Status and context

This blend and its individual components have not been approved as a medicinal product and are supplied solely as research material. In the context of sport, both GHRH analogues and growth hormone secretagogues are on the World Anti-Doping Agency’s (WADA) Prohibited List. When conducting research, always document the purity and batch number to ensure that experiments remain reproducible and traceable.

The fixed ratio within the blend has a practical advantage: it makes it easier to compare experiments with one another than if two separate peptides were mixed anew each time. Record this ratio and the batch number for each experiment.

The blend is supplied as a lyophilised powder and reconstituted in the laboratory using bacteriostatic water. The steps below describe only the laboratory procedures for research purposes.

1. 1Allow the vial and the bacteriostatic water to reach room temperature.
2. 2Wipe the rubber stoppers of both vials with an alcohol wipe.
3. 3Allow the bacteriostatic water to run slowly down the side of the vial; do not direct it straight onto the powder.
4. 4Gently swirl the vial until everything has dissolved; do not shake.
5. 5Store the solution in the fridge and label it with the date and batch number.

You can find supplies such as bacteriostatic water, insulin syringes and alcohol wipes under ‘Lab & Accessories’. This is a laboratory instruction and does not constitute dosage advice for consumption.

Working with a blend

A blend contains two components in a single vial. You should therefore not only record the total quantity, but also take into account in your calculations that the ratio between the two molecules is fixed. Careful, traceable documentation is particularly important for combination products.

Store the blend in freeze-dried (powder) form in a cool, dark place for maximum stability.

Practical storage tips

• Powder form: freezer (-20 °C) for long-term storage; fridge (2–8 °C) for short-term storage.
• After reconstitution: store refrigerated (2–8 °C) and use within a few weeks.
• Avoid direct light, heat and repeated temperature changes.
• Write the reconstitution date and batch number on the vial.

Careful storage preserves the purity and integrity of both components in the blend.